Inovio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Inovio Pharmaceuticals's earnings have been declining at an average annual rate of -10.2%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been declining at an average rate of 23.6% per year.
Key information
-10.2%
Earnings growth rate
9.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -23.6% |
Return on equity | -132.3% |
Net Margin | -17,423.5% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates
May 15Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates
May 13Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?
Oct 23Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug
Oct 13Inovio Pharmaceuticals: Long On Promise, Short On Results
Sep 27Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M
Aug 09Inovio: After All These Years
Jul 19Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
Apr 15Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Mar 21Inovio Undervalued On Potential 2022 Catalyst
Jan 26Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Dec 31Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side
Nov 18Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Sep 24Inovio: Simply Cannot Be Ignored
Sep 03Inovio Has 4 Sources Of Potential Value
Jun 23Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Jun 11Inovio stock trades higher defying insider sale
Jun 07Revenue & Expenses Breakdown
How Inovio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1 | -125 | 45 | 0 |
31 Dec 23 | 1 | -135 | 48 | 0 |
30 Sep 23 | 1 | -165 | 36 | 0 |
30 Jun 23 | 10 | -168 | 38 | 0 |
31 Mar 23 | 10 | -241 | 73 | 0 |
31 Dec 22 | 10 | -280 | 76 | 0 |
30 Sep 22 | 11 | -332 | 90 | 0 |
30 Jun 22 | 2 | -355 | 92 | 0 |
31 Mar 22 | 2 | -328 | 56 | 0 |
31 Dec 21 | 2 | -304 | 54 | 0 |
30 Sep 21 | 7 | -221 | 48 | 0 |
30 Jun 21 | 6 | -142 | 45 | 0 |
31 Mar 21 | 6 | -188 | 44 | 0 |
31 Dec 20 | 7 | -166 | 37 | 0 |
30 Sep 20 | 2 | -180 | 37 | 0 |
30 Jun 20 | 3 | -222 | 33 | 0 |
31 Mar 20 | 3 | -123 | 28 | 0 |
31 Dec 19 | 4 | -119 | 27 | 0 |
30 Sep 19 | 6 | -115 | 24 | 0 |
30 Jun 19 | 7 | -117 | 25 | 0 |
31 Mar 19 | 32 | -94 | 27 | 0 |
31 Dec 18 | 30 | -97 | 29 | 0 |
30 Sep 18 | 37 | -86 | 32 | 0 |
30 Jun 18 | 37 | -95 | 31 | 0 |
31 Mar 18 | 33 | -97 | 30 | 0 |
31 Dec 17 | 42 | -88 | 28 | 0 |
30 Sep 17 | 42 | -93 | 27 | 0 |
30 Jun 17 | 52 | -80 | 27 | 0 |
31 Mar 17 | 38 | -89 | 26 | 0 |
31 Dec 16 | 35 | -74 | 24 | 0 |
30 Sep 16 | 33 | -65 | 22 | 0 |
30 Jun 16 | 44 | -39 | 20 | 0 |
31 Mar 16 | 44 | -27 | 19 | 0 |
31 Dec 15 | 41 | -29 | 18 | 0 |
30 Sep 15 | 37 | -19 | 17 | 0 |
30 Jun 15 | 15 | -31 | 16 | 0 |
31 Mar 15 | 13 | -36 | 16 | 0 |
31 Dec 14 | 10 | -36 | 16 | 0 |
30 Sep 14 | 10 | -44 | 16 | 0 |
30 Jun 14 | 17 | -68 | 16 | 0 |
31 Mar 14 | 14 | -68 | 15 | 0 |
31 Dec 13 | 13 | -66 | 14 | 0 |
30 Sep 13 | 13 | -51 | 12 | 0 |
30 Jun 13 | 4 | -27 | 12 | 0 |
Quality Earnings: INO is currently unprofitable.
Growing Profit Margin: INO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: INO has a negative Return on Equity (-132.29%), as it is currently unprofitable.